1
|
Güner G, Aktaş BY, Başal FB, Demirkazık A, Gürsoy P, Demirci U, Erman M, Yumuk PF, Şenler FÇ, Çakar B, Çiçin İ, Öztürk A, Coşkun HŞ, Çubukçu E, Işıkdoğan A, Ölmez ÖF, Tatlı AM, Karaağaç M, Şakalar T, Eralp Y, Korkmaz T, Kılıçkap S. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC? J Cancer Res Clin Oncol 2023; 149:13271-13277. [PMID: 37480524 DOI: 10.1007/s00432-023-05190-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 07/14/2023] [Indexed: 07/24/2023]
Abstract
PURPOSE Anaplastic lymphoma kinase (ALK) mutations occurs in approximately 3-5% of patients with non-small cell lung cancer (NSCLC). Pleural involvement/effusion is common in ALK-positive patients with NSCLC at baseline. The aim of the study was to evaluate the characteristics of ALK-positive patients who have Ple-I/E. METHODS In this multicenter study, patients with ALK-positive NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median progression-free survival (PFS), and overall survival (OS) were evaluated in 362 ALK-positive patients with NSCLC. RESULTS Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (range 21-85) years. All patients' histology was adenocarcinoma (100%). At baseline, 57 (15.7%) patients had Ple-I/E. There was no association between Ple-I/E and gender, lung metastasis, or distant lymphadenopathy (LAP) metastasis. The frequencies of liver, brain, and bone metastases were significantly higher in ALK-positive patients without Ple-I/E compared to those with Ple-I/E (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.001; 20.6% vs 8.9%, p = 0.002). The median PFS was longer in ALK-positive patients who had Ple-I/E (18.7 vs 10.6 months, p = 0.017). Similarly, the median OS was longer in ALK-positive patients who had Ple-I/E (44.6 vs 22.6 months, p = 0.051). CONCLUSION Brain, liver, and bone metastases were lower in ALK-positive patients with Ple-I/E. Patients presented with Ple-I/E were prone to have better PFS and OS.
Collapse
Affiliation(s)
- Gürkan Güner
- Department of Medical Oncology, Hacettepe University Cancer Institute, Sihhiye, 06100, Ankara, Turkey.
| | - Burak Yasin Aktaş
- Department of Medical Oncology, Hacettepe University Cancer Institute, Sihhiye, 06100, Ankara, Turkey
| | | | - Ahmet Demirkazık
- Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey
| | - Pınar Gürsoy
- Department of Medical Oncology, Ege University Faculty of Medicine, Izmir, Turkey
| | - Umut Demirci
- Memorial Ankara Hospital, Medical Oncology Unit, Ankara, Turkey
| | - Mustafa Erman
- Department of Medical Oncology, Hacettepe University Cancer Institute, Sihhiye, 06100, Ankara, Turkey
| | - Perran Fulden Yumuk
- Division of Medical Oncology, Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey
- Division of Medical Oncology, Koç University, School of Medicine, Istanbul, Turkey
| | - Filiz Çay Şenler
- Department of Medical Oncology, Ankara University Faculty of Medicine, Ankara, Turkey
| | - Burcu Çakar
- Department of Medical Oncology, Ege University Faculty of Medicine, Izmir, Turkey
| | - İrfan Çiçin
- Department of Medical Oncology, Trakya University Faculty of Medicine, Edirne, Turkey
| | - Akın Öztürk
- Department of Medical Oncology, Sureyyapasa Chest Disease Hospital, Istanbul, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - Erdem Çubukçu
- Department of Medical Oncology, Bursa Uludag University Faculty of Medicine, Bursa, Turkey
| | - Abdurrahman Işıkdoğan
- Department of Medical Oncology, Dicle University Faculty of Medicine, Diyarbakır, Turkey
| | - Ömer Fatih Ölmez
- Department of Medical Oncology, Medipol Mega Hospitals Complex (University Hospital), Istanbul, Turkey
| | - Ali Murat Tatlı
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - Mustafa Karaağaç
- Department of Medical Oncology, Necmettin Erbakan University School of Medicine, Konya, Turkey
| | - Teoman Şakalar
- Department of Medical Oncology, Erciyes University School of Medicine, Kayseri, Turkey
| | - Yeşim Eralp
- Department of Medical Oncology, Acıbadem University, Maslak Acıbadem Hospital, Istanbul, Turkey
| | - Taner Korkmaz
- Department of Medical Oncology, Mehmet Ali Aydınlar Acıbadem University Faculty of Medicine, Istanbul, Turkey
| | - Saadettin Kılıçkap
- Department of Medical Oncology, Istinye University Faculty of Medicine, Istanbul, Turkey
| |
Collapse
|
2
|
Canatan D, Sonmez Y, Yılmaz O, Coşkun HŞ, Göksu SS, Uçar S, Aktekin MR. The importance microRNAs as a biomarker in lung cancer. Acta Biomed 2023; 94:e2023045. [PMID: 36786270 PMCID: PMC9987486 DOI: 10.23750/abm.v94i1.13334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 06/10/2022] [Accepted: 11/27/2022] [Indexed: 02/15/2023]
Abstract
INTRODUCTION Lung cancer (LC) is the most common cancer in the world.Well known causes are long term smoking, environmental influences and genetic variations. LC is divided into two main types based on their histological phenotypes; small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC). The high specificity of these new screening methods, which are non-invasive, safe, inexpensive and simple to perform, is important in the early diagnosis and prognosis of cancer. MicroRNAs are significant biomarkers on the diagnosis metastasis and targeted therapies of NSCLC. In our study, we aimed to investigate the potential of using microRNAs as a biomarker in the early diagnosis of lung cancer. MATERIAL AND METHOD Twenty patients diagnosed with lung cancer and twenty healthy individuals of the same age and gender were selected as the control group. Sixteen microRNAs were studied from blood samples. RESULT Sixteen miRNAs (Let -7c, Let-7g, miR-1, miR-21, miR-29a, miR-31, miR-34a, miR 103a, miR-141, miR-155, miR-193b, miR-200b, miR-205, miR-340, miR-486, miR-708) were selected for tests and MiR 181 and miR 192 were used as the endogenous control group in line with their binding potentials and gene expression levels. The most specific and sensitive miRNAs were mirR-29a, miR-103a, and miR486 according to endogen controls in patients and healthy subjects. DISCUSSION A meta-analysis study showed that circulating miRNAs could be promising biomarkers for early diagnosis of lung cancer. Overall, 17 studies were included evaluating 35 miRNA markers and 19 miRNA panels in serum or plasma. The potential role of circulating miRNAs for non-invasive lung screening has been highlighted. In conclusion, there is a need for further validation studies for the use of three miRNAs as a biomarker in the early diagnosis and prognosis of lung cancer.
Collapse
Affiliation(s)
- Duran Canatan
- Vocational School of Health Services of Antalya Bilim University -Antalya Turkey Medical Director of Antalya Genetic Diseases Assessment Center Çıplaklı Mah. Akdeniz Bulvarı No:290 A Döşemealtı/Antalya .
| | | | | | - Hasan Şenol Coşkun
- Akdeniz University, Faculty of Medicine, Department of Medical Oncology- Antalya- Turkey.
| | - Sema Sezgin Göksu
- Akdeniz University, Faculty of Medicine, Department of Medical Oncology- Antalya- Turkey.
| | - Selda Uçar
- Akdeniz University, Faculty of Medicine, Department of Medical Oncology- Antalya- Turkey.
| | - Mehmet Rıfkı Aktekin
- Akdeniz University, Faculty of Medicine, Department of Public Health - Antalya- Turkey.
| |
Collapse
|
3
|
Gürbüz M, Kiliçkap S, Bilici A, Karadurmuş N, Sezer A, Şendur MAN, Paydaş S, Artaç M, Fulden Yumuk P, Gürsoy P, Uysal M, Şenol Coşkun H, Tatli AM, Selçukbiricik F, Dişel U, Köksoy EB, Güven DC, Uğrakli M, Akkuş E, Yücel Ş, Erol C, Karakaya S, Şakalar T, Khanmammadov N, Paksoy N, Demirkazik A. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group. Medicine (Baltimore) 2022; 101:e32368. [PMID: 36550824 PMCID: PMC9771320 DOI: 10.1097/md.0000000000032368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Crizotinib is a multikinase inhibitor, effective in non-small cell lung cancer (NSCLC) harboring mesenchymal-epidermal transition (MET) alterations. Although small prospective studies showed efficacy and safety of crizotinib in NSCLC with MET alterations, there is limited real-life data. Aim of this study is to investigate real-life efficacy and safety of crizotinib in patients with advanced NSCLC harboring MET alterations. This was a retrospective, multicenter (17 centers) study of Turkish Oncology Group. Patients' demographic, histological data, treatment, response rates, survival outcomes, and toxicity data were collected. Outcomes were presented for the study population and compared between MET alteration types. Total of 62 patients were included with a median age of 58.5 (range, 26-78). Major histological type was adenocarcinoma, and 3 patients (4.8%) had sarcomatoid component. The most common MET analyzing method was next generation sequencing (90.3%). MET amplification and mutation frequencies were 53.2% (n = 33) and 46.8% (n = 29), respectively. Overall response rate and disease control rate were 56.5% and 74.2% in whole study population, respectively. Median progression free survival (PFS) was 7.2 months (95% confidence interval [CI]: 3.8-10.5), and median overall survival (OS) was 18.7 months (95% CI: 13.7-23.7), regardless of treatment line. Median PFS was 6.1 months (95% CI: 5.6-6.4) for patients with MET amplification, whereas 14.3 months (95% CI: 6.7-21.7) for patients with MET mutation (P = .217). Median PFS was significantly longer in patients who have never smoked (P = .040), have good performance score (P < .001), and responded to the treatment (P < .001). OS was significantly longer in patients with MET mutation (25.6 months, 95% CI: 15.9-35.3) compared to the patients with MET amplification (11.0 months; 95% CI: 5.2-16.8) (P = .049). In never-smokers, median OS was longer than smoker patients (25.6 months [95% CI: 11.8-39.3] vs 16.5 months [95% CI: 9.3-23.6]; P = .049). The most common adverse effects were fatigue (50%), peripheral edema (21%), nausea (29%) and diarrhea (19.4%). Grade 3 or 4 adverse effects were observed in 6.5% of the patients. This real-life data confirms efficacy and safety of crizotinib in the treatment of advanced NSCLC harboring MET alteration.
Collapse
Affiliation(s)
- Mustafa Gürbüz
- Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
- * Correspondence: Mustafa Gürbüz, Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara 06100, Turkey (e-mail: ; )
| | - Saadettin Kiliçkap
- İstinye University Faculty of Medicine, Liv Ankara Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Ahmet Bilici
- İstanbul Medipol University Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
| | - Nuri Karadurmuş
- University of Health Sciences, Department of Medical Oncology, Gülhane Training and Research Hospital, Ankara, Turkey
| | - Ahmet Sezer
- Başkent University Faculty of Medicine, Department of Medical Oncology, Adana, Turkey
| | - Mehmet Ali Nahit Şendur
- Yildirim Beyazit University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| | - Semra Paydaş
- Çukurova University Faculty of Medicine, Department of Medical Oncology, Adana, Turkey
| | - Mehmet Artaç
- Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, Turkey
| | | | - Pinar Gürsoy
- Ege University Faculty of Medicine, Department of Medical Oncology, İzmir, Turkey
| | - Mükremin Uysal
- Medstar Antalya Hospital, Department of Medical Oncology, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Akdeniz University Faculty of Medicine, Department of Medical Oncology, Antalya, Turkey
| | - Ali Murat Tatli
- Akdeniz University Faculty of Medicine, Department of Medical Oncology, Antalya, Turkey
| | | | - Umut Dişel
- Acibadem Adana Hospital, Department of Medical Oncology, Adana, Turkey
| | - Elif Berna Köksoy
- Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| | - Deniz Can Güven
- Hacettepe University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| | - Muzaffer Uğrakli
- Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, Turkey
| | - Erman Akkuş
- Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey
| | - Şebnem Yücel
- Yildirim Beyazit University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| | - Cihan Erol
- Yildirim Beyazit University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| | - Serdar Karakaya
- Atatürk Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Medical Oncology, Ankara, Turkey
| | - Teoman Şakalar
- Necip Fazil City Hospital, Department of Medical Oncology, Kahramanmaraş, Turkey
| | - Nijat Khanmammadov
- İstanbul University Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
| | - Nail Paksoy
- Tekirdağ Dr. İsmail Fehmi Cumalioğlu City Hospital, Department of Medical Oncology, Tekirdağ, Turkey
| | - Ahmet Demirkazik
- Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| |
Collapse
|
4
|
Yekedüz E, Özbay MF, Çağlayan D, Yıldırım A, Erol C, Yıldırım HÇ, Tunç S, Özyurt N, Özdemir F, Şendur MAN, Işıkdoğan A, Kılıçkap S, Ürün Y, Yalçın Ş, Artaç M, Coşkun HŞ, Utkan G. Clinical outcomes of concomitant use of proton pump inhibitors and regorafenib in patients with metastatic colorectal cancer: a multicenter study. Eur J Clin Pharmacol 2022; 78:1973-1979. [PMID: 36266366 DOI: 10.1007/s00228-022-03403-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 10/10/2022] [Indexed: 11/30/2022]
Abstract
AIM To compare survival outcomes, response rates, and adverse events (AEs) in proton pump inhibitor (PPI) user and non-user patients with metastatic colorectal cancer (mCRC) treated with regorafenib. METHODS We included 272 patients with mCRC treated with regorafenib in this study. Patients were divided into two categories according to their status of PPI use. The primary endpoint was overall survival (OS). The secondary endpoints were time to treatment failure (TTF), response rates, and safety. To exclude immortal time bias in survival analyses, we compared PPI non-user patients and all patients. RESULTS There were 141 and 131 patients in the PPI non-user and user groups. Baseline characteristics were similar in each group. Pantoprazole was the most used PPI. At the median 35.2 (95% confidence interval (CI): 32.6-37.9) months follow-up, the median OS was similar in PPI non-user and all patients (6.9 months (95% CI: 5.3-8.5) and 7.7 months (95% CI:6.6-8.8), p = 0.913). TTF was also similar in PPI non-user and all patients (3.3 months (95% CI: 2.7-3.9) and 3.5 months (95% CI: 3.0-4.0), p = 0.661). In multivariable analysis, no statistically significant difference was observed between PPI user and non-user groups in OS and TTF (hazard ratio (HR), 0.99; 95% CI, 0.77-1.28; p = 0.963 for OS; HR, 0.93; 0.77-1.20, p = 0.598 for TTF). The objective response rates (ORR) were similar in the PPI non-user and user groups (19.8% and 16.8%, p = 0.455). The rates of any grade AEs were also similar in each group. CONCLUSION This study found no worse outcome in the combined use of PPI and regorafenib among patients with mCRC.
Collapse
Affiliation(s)
- Emre Yekedüz
- Department of Medical Oncology, Faculty of Medicine, Ankara University, 06590, Ankara, Turkey. .,Cancer Research Institute, Ankara University, Ankara, Turkey.
| | - Mehmet Fatih Özbay
- Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| | - Dilek Çağlayan
- Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
| | - Atila Yıldırım
- Department of Medical Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
| | - Cihan Erol
- Department of Medical Oncology, University Faculty of Medicine, Faculty of Medicine Ankara, Ankara Yıldırım Beyazıt University, Ankara, Turkey
| | - Hasan Çağrı Yıldırım
- Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - Sezai Tunç
- Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır, Turkey
| | - Neslihan Özyurt
- Medical Oncology Clinic, Prof. Dr. İlhan Özdemir State Hospital, Giresun, Turkey
| | - Feyyaz Özdemir
- Department of Medical Oncology, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey
| | - Mehmet Ali Nahit Şendur
- Department of Medical Oncology, University Faculty of Medicine, Faculty of Medicine Ankara, Ankara Yıldırım Beyazıt University, Ankara, Turkey
| | - Abdurrahman Işıkdoğan
- Department of Medical Oncology, Faculty of Medicine, Dicle University, Diyarbakır, Turkey
| | - Saadettin Kılıçkap
- Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.,Faculty of Medicine, Liv Hospital Medical Oncology Clinic, İstinye University, Ankara, Turkey
| | - Yüksel Ürün
- Department of Medical Oncology, Faculty of Medicine, Ankara University, 06590, Ankara, Turkey.,Cancer Research Institute, Ankara University, Ankara, Turkey
| | - Şuayib Yalçın
- Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, Turkey
| | - Mehmet Artaç
- Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| | - Güngör Utkan
- Department of Medical Oncology, Faculty of Medicine, Ankara University, 06590, Ankara, Turkey.,Cancer Research Institute, Ankara University, Ankara, Turkey
| |
Collapse
|
5
|
Altınışık M, Kocabıyık B, Arıkan F, Şevik HY, Coşkun HŞ. The relationship between hope levels and unmet needs of caregivers of advanced cancer patients†. Jpn J Nurs Sci 2022; 19:e12482. [PMID: 35274446 DOI: 10.1111/jjns.12482] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 12/22/2021] [Accepted: 02/07/2022] [Indexed: 11/29/2022]
Abstract
AIM The effects in cultural and health provisions can lead to different unmet support needs. Hope is seen as an important support, a supportive power, and an efficient coping strategy for cancer caregivers. The purpose of this study in Turkish society is to determine supportive care needs of caregivers of cancer patients, to determine the hope levels of those caring for cancer patients and foresee how variables and hope can trigger needs. METHODS To identify the unmet needs and hope levels of caregivers of advanced cancer patients in Turkish society. Data were collected using the Supportive Care Needs of Caregivers Scale and Herth Hope Index. RESULTS More than half of the advanced cancer caregivers (56.51%) reported unmet care needs. Their unmet needs and hope levels were above average. Regression analysis showed the total score for hope was related to health care and information needs, work-social needs. CONCLUSION Hope was related to health care and information needs and work-social needs. Oncology nurses should focus on the unmet needs of caregivers, taking into account their cultural differences in order to raise their hopes.
Collapse
Affiliation(s)
- Müge Altınışık
- Department of Internal Medicine Nursing, Akdeniz University Faculty of Nursing, Antalya, Turkey
| | | | - Fatma Arıkan
- Department of Internal Medicine Nursing, Akdeniz University Faculty of Nursing, Antalya, Turkey
| | | | | |
Collapse
|
6
|
Canatan D, Yılmaz Ö, Sönmez Y, Çim A, Baykara M, Savaş M, Coşkun HŞ, Göksu SS, Aktekin MR. Use of MicroRNAs as biomarkers in the early diagnosis of prostate cancer. Acta Biomed 2022; 93:e2022089. [PMID: 35775783 PMCID: PMC9335414 DOI: 10.23750/abm.v93i3.11642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Subscribe] [Scholar Register] [Received: 04/17/2021] [Accepted: 10/04/2021] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Prostate cancer (PCa) is a common type of cancer in western countries and prominent cause of mortality in men. The aim of the study was to analyze circulating miRNAs as biomarkers in the sera of healthy individuals and prostate cancer cases without biopsy. MATERIAL AND METHODS Twenty prostate cases, age (mean and range) 61,4±12.1 (45-73), and twenty healthy men, age 59,3±11.2 (44-70) were included to the study. The mean and range of prostate spesific antigen (PSA) in cancer cases and healthy individuals were 6.79±2.84 ng/ml (2.25-14.7) and 3.8±2.2 ng/ml (1.3-7.8) respectively. RESULTS Seven miRNAs including two internal controls (Let7c, miR125b, miR141, miR145, miR 155, miR181 ve miR192) were evaluated in two groups. The level of miR141 was significantly lower in PCa cases than healthy individuals (p=0,004), and miR155 was significantly higher (p=0,005) in PCa cases. Both miRNAs were explored sensitive and spesific in the ROC analysis. Tumor mass were found to be associated with the level of miR-125b and miR-145. Conclusion; validation studies are required in wider patient groups in the subject of tumor effect and miRNA biomarkers in prostate cancer.
Collapse
Affiliation(s)
- Duran Canatan
- Antalya Genetic Diseases Center, Antalya, Turkey, Vocational School of Health Services of Antalya Bilim University -Antalya Turkey
| | - Özlem Yılmaz
- Akdeniz University, Deparment of Genetics, Antalya, Turkey
| | - Yonca Sönmez
- Akdeniz University, Faculty of Medicine, Deparment of Public Health, Antalya, Turkey; Lara Anadolu Hospital, Department of Urology, Antalya, Turkey
| | - Abdullah Çim
- Antalya Genetic Diseases Center, Antalya, Turkey
| | - Mehmet Baykara
- Memorial Hospital, Department of Urology, Antalya, Turkey
| | - Murat Savaş
- Akdeniz University, Medical Faculty, Department of Medical Oncology, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Vocational School of Health Services of Antalya Bilim University -Antalya Turkey
| | - Sema Sezgin Göksu
- Vocational School of Health Services of Antalya Bilim University -Antalya Turkey
| | - Mehmet Rıfkı Aktekin
- Akdeniz University, Faculty of Medicine, Deparment of Public Health, Antalya, Turkey; Lara Anadolu Hospital, Department of Urology, Antalya, Turkey
| |
Collapse
|
7
|
Bozcuk H, Coşkun HŞ, İlhan Y, Göksu SS, Yıldız M, Bayram S, Yerlikaya T, Koçer M, Artaç M, Uğraklı M, Ouisupov A, Aydeniz A, Şahin D, Yalçın G, Saatçi M, Mutlu H, Yıldırım M. Prospective external validation of an updated algorithm to quantify risk of febrile neutropenia in cancer patients after a cycle of chemotherapy. Support Care Cancer 2021; 30:2621-2629. [PMID: 34816328 DOI: 10.1007/s00520-021-06681-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2021] [Accepted: 11/03/2021] [Indexed: 11/25/2022]
Abstract
PURPOSE Febrile neutropenia resulting from chemotherapy is a significant cause of morbidity and mortality in cancer patients. We had previously published the associates of the risk of febrile neutropenia, and this study now extends and modifies the previous model as well as tests its external validity. METHODS We have recruited documented febrile neutropenia cases with solid tumors, in addition to a selected control group of cancer patients from one institution treated between 2015 and 2019. We then united our sample with our previously published original derivation group, to modify and update our previous model by logistic regression analysis. Additionally, consecutive cancer patients from 5 institutions were recruited in 2020 to test external validity of the resultant algorithm. RESULTS A total of 4075 cycles of chemotherapy in 1282 cases were recruited in the updated, new model derivation group, and a total of 8 variables were selected for the updated algorithm. In the new external validation group, 653 cycles of chemotherapy in 624 patients were analyzed, to indicate that after cycles without prophylactic granulocyte colony-stimulating factor (GCSF) usage, the algorithm yielded a sensitivity value of 91%, specificity of 40%, and an area under curve (AUC) figure of 0.78, when a risk cutoff threshold value of ≥ 0.20 is chosen. This algorithm is now embedded in a web application for free clinical use. CONCLUSION Our algorithm identifies and quantifies the risk of febrile neutropenia in cancer patients. Further studies are required to improve this model with additional predictors.
Collapse
Affiliation(s)
- Hakan Bozcuk
- Department of Medical Oncology, Medical Park Hospital, Lara, Antalya, Turkey.
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University Medical Faculty, Antalya, Turkey
| | - Yusuf İlhan
- Department of Medical Oncology, Akdeniz University Medical Faculty, Antalya, Turkey
| | - Sema Sezgin Göksu
- Department of Medical Oncology, Akdeniz University Medical Faculty, Antalya, Turkey
| | - Mustafa Yıldız
- Department of Medical Oncology, SBU Antalya SUAM, Antalya, Turkey
| | - Selami Bayram
- Department of Medical Oncology, SBU Antalya SUAM, Antalya, Turkey
| | - Tahir Yerlikaya
- Department of Medical Oncology, SBU Antalya SUAM, Antalya, Turkey
| | - Murat Koçer
- Department of Medical Oncology, SBU Antalya SUAM, Antalya, Turkey
| | - Mehmet Artaç
- Department of Medical Oncology, Necmettin Erbakan University Meram Medical Faculty, Konya, Turkey
| | - Muzaffer Uğraklı
- Department of Medical Oncology, Necmettin Erbakan University Meram Medical Faculty, Konya, Turkey
| | - Ayberk Ouisupov
- Department of Medical Oncology, Medical Park Hospital, Lara, Antalya, Turkey
| | - Alev Aydeniz
- Department of Medical Oncology, Medical Park Hospital, Lara, Antalya, Turkey
| | - Dilhun Şahin
- Department of Medical Oncology, Medical Park Hospital, Lara, Antalya, Turkey
| | - Gözde Yalçın
- Department of Medical Oncology, Medical Park Hospital, Lara, Antalya, Turkey
| | - Meliha Saatçi
- Department of Medical Oncology, Medical Park Hospital, Lara, Antalya, Turkey
| | - Hasan Mutlu
- Department of Medical Oncology, Medical Park Hospital, Lara, Antalya, Turkey
| | - Mustafa Yıldırım
- Department of Medical Oncology, Sanko University, Gaziantep, Turkey
| |
Collapse
|
8
|
Arıkan F, Uçar MA, Kondak Y, Tekeli A, Kartöz F, Özcan K, Göksu SS, Coşkun HŞ. Corrigendum to "Reasons for complementary therapy use by cancer patients, information sources and communication with health professionals" [Complement Ther Med 44 (2019) 157-161]. Complement Ther Med 2021; 63:102790. [PMID: 34799206 DOI: 10.1016/j.ctim.2021.102790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Affiliation(s)
- Fatma Arıkan
- Akdeniz University, Faculty of Nursing, Antalya, Turkey.
| | - Mürvet Artuk Uçar
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Yasemin Kondak
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Aysel Tekeli
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Funda Kartöz
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Keziban Özcan
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Sema Sezgin Göksu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
9
|
Koçer M, Muallaoğlu S, Çetin B, Coşkun HŞ, Karahan N, Gürdal O. Second Primary Tumors in Patients with Gastrointestinal Stromal Tumors: A Single-Center Experience. Medicina (Kaunas) 2021; 57:medicina57050494. [PMID: 34068309 PMCID: PMC8153290 DOI: 10.3390/medicina57050494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/04/2021] [Revised: 05/07/2021] [Accepted: 05/11/2021] [Indexed: 11/18/2022]
Abstract
Background and Objectives: In this study, we investigated the frequency and type of second primary malignant tumors (SPMTs) accompanying gastrointestinal stromal tumors (GISTs), patient and tumor characteristics, and follow-up and survival data. Materials and Methods: We included 20 patients with SPMTs from a total of 103 patients with GISTs in a single center in Turkey. At the time of GIST diagnosis, patient age, sex, presentation symptoms, localization, pathological features of the tumor, stage, recurrence risk scoring for localized disease, treatments received, time of SPMT association, follow-up times, and survival analysis were recorded for each patient. Localization, histopathology, and stage of SPMT accompanying GISTs were also recorded accordingly. Results: SPMT was detected in 19.4% of patients with GISTs. Of the patients, 50% were men and 50% were women. The mean age at the time of diagnosis of GIST was 63.8 ± 10.81 years (range: 39–77 years). Of the GISTs, 60% were localized in the stomach, 25% in the small intestine, and 70% were at low risk. Of the SPMTs, 60% were in the gastrointestinal system. SPMTs were diagnosed as synchronous with GISTs in 50% of the patients. The mean follow-up period of the patients from the diagnosis of GIST was 45.6 (0.43–129.6) months. When the data were finalized, 5% died due to GIST, 35% died due to SPMT, and 15% died due to non-disease-related causes. Conclusions: SPMT was detected in 19.4% of patients with GISTs. GISTs were frequently located in the stomach, and most of them were at low risk. The most common SPMTs were gastrointestinal system tumors, and their coexistence was found to be synchronous. Most patients died due to SPMT during follow-up.
Collapse
Affiliation(s)
- Murat Koçer
- Medical Oncology Subdivision, Department of Internal Medicine, Antalya Training and Research Hospital, Health Sciences University, Muratpaşa, Antalya 07100, Turkey
- Correspondence: ; Tel.: +90-542-513-9666
| | - Sadık Muallaoğlu
- Medical Oncology Clinic, Private Iskenderun Gelişim Hospital, Iskenderun 31200, Turkey;
| | - Bülent Çetin
- Medical Oncology Subdivision, Department of Internal Medicine, Süleyman Demirel University Faculty of Medicine, Isparta 32260, Turkey;
| | - Hasan Şenol Coşkun
- Medical Oncology Subdivision, Department of Internal Medicine, Akdeniz University Faculty of Medicine, Konyaaltı, Antalya 07070, Turkey;
| | - Nermin Karahan
- Department of Pathology, Süleyman Demirel University Faculty of Medicine, Isparta 32260, Turkey;
| | - Osman Gürdal
- Department of Biostatistics and Medical Informatics, Süleyman Demirel University Faculty of Medicine, Isparta 32260, Turkey;
| |
Collapse
|
10
|
Canatan D, Sönmez Y, Yılmaz Ö, Çim A, Coşkun HŞ, Sezgin Göksu S, Ucar S, Aktekin MR. MicroRNAs as biomarkers for breast cancer. Acta Biomed 2021; 92:e2021028. [PMID: 33988168 PMCID: PMC8182592 DOI: 10.23750/abm.v92i2.9678] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Subscribe] [Scholar Register] [Received: 05/01/2020] [Accepted: 05/05/2020] [Indexed: 12/11/2022]
Abstract
Breast cancer is the most common type of cancer among women and the most frequent cause of death due to cancer among women. The lack of standard biomarkers in the early diagnosis of breast cancer, microRNAs (miRNA) have been of interest recently. Although, miRNAs are 19-24 nucleotide-long non-coding RNA species, they have crucial roles in many areas from organogenesis to carcinogenesis. This study has been conducted to investigate miR 21, miR 27b, miR 125a, miR 155, miR 200c, miR 335 miR373 as biomarkers in the early diagnosis of breast cancer; a selection based on the literature. Two miRNAs, miR 181 and miR 192 were selected as the endogenous control. MiRNAs were obtained from 5 cc blood samples taken from 20 breast cancer patients and 20 healthy people. 10 microRNAs were studied using Real Time PCR method. As a result, the quantities of miR 21, miR155 and miR125 were significantly higher in the breast cancer group than in healthy controls. We suggest that performing validation studies in wider populations can help the use of miRNAs as biomarkers in the early diagnosis of breast cancer.
Collapse
Affiliation(s)
- Duran Canatan
- Antalya Genetic Diseases Diagnosis Center - Antalya- Turkey.
| | - Yonca Sönmez
- Akdeniz University, Faculty of Medicine, Department of Public Health - Antalya- Turkey.
| | - Özlem Yılmaz
- Antalya Genetic Diseases Diagnosis Center - Antalya- Turkey.
| | - Abdullah Çim
- Antalya Genetic Diseases Diagnosis Center - Antalya- Turkey.
| | - Hasan Şenol Coşkun
- Akdeniz University, Faculty of Medicine, Department of Medical Oncology- Antalya- Turkey.
| | - Sema Sezgin Göksu
- Akdeniz University, Faculty of Medicine, Department of Medical Oncology- Antalya- Turkey.
| | - Selda Ucar
- Akdeniz University, Faculty of Medicine, Department of Medical Oncology- Antalya- Turkey.
| | - Mehmet Rıfkı Aktekin
- Akdeniz University, Faculty of Medicine, Department of Public Health - Antalya- Turkey.
| |
Collapse
|
11
|
Eryılmaz MK, Tazegul G, Ünal B, Müsri FY, Güzel HG, Coşkun HŞ. Rapidly developing facial and intertriginous hyperpigmentation with acral erythema after docetaxel infusion. J Cancer Res Ther 2021; 17:293-294. [PMID: 33723176 DOI: 10.4103/jcrt.jcrt_385_17] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
| | - Gokhan Tazegul
- Department of Internal Medicine, School of Medicine, Akdeniz University, Antalya, Turkey
| | - Betül Ünal
- Department of Pathology, School of Medicine, Akdeniz University, Antalya, Turkey
| | - Fatma Yalçin Müsri
- Department of Medical Oncology, School of Medicine, Akdeniz University, Antalya, Turkey
| | - Halil Göksel Güzel
- Department of Internal Medicine, School of Medicine, Akdeniz University, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, School of Medicine, Akdeniz University, Antalya, Turkey
| |
Collapse
|
12
|
Arıkan F, Körükçü Ö, Küçükçakal A, Coşkun HŞ. Determination of Self-Efficacy, Body Image and Sexual Adjustment of Women with Breast Cancer. Eur J Breast Health 2020; 16:282-289. [PMID: 33062970 DOI: 10.5152/ejbh.2020.5188] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2019] [Accepted: 02/09/2020] [Indexed: 11/22/2022]
Abstract
Objective The determination of the self-efficacy levels of women with breast cancer, as well as their body image (BI) and sexual adjustment status, is very important for their empowerment. The purpose of this study was to determine the self-efficacy, BI, and sexual adjustment levels of women with breast cancer that received chemotherapy, as well as the factors that influence these characteristics. Materials and Methods This descriptive study included women (n=117) that were diagnosed with breast cancer, had received at least two sessions of chemotherapy. The study data were collected using a sociodemographic form which also included questions about the breast cancer. Also, the Strategies Used by Patients to Promote Health (SUPPH) scale, and the Sexual Adjustment and Body Image Scale (SABIS) were used. Results The average age of the women participating in the study was 56.64±8.78 years. In the study, the women with breast cancer undergone a mastectomy, and those who lacked the support of their spouses, as well as education on sexuality, obtained lower scores on the SUPPH and SABIS. There was a positive correlation between the self-efficacy in self-care and sexual adjustment, sexual functions, and body images. Conclusion This study found that the women with breast cancer had low self-efficacy, and that their former sexual adjustment and low body image had a negative effect on their post-diagnosis sexual functions.
Collapse
Affiliation(s)
- Fatma Arıkan
- Akdeniz University Faculty of Nursing, Antalya, Turkey
| | - Öznur Körükçü
- Akdeniz University Faculty of Nursing, Antalya, Turkey
| | - Ayşegül Küçükçakal
- Department of Medical Oncology, Akdeniz University Hospital, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
13
|
Alkan A, Yaşar A, Güç ZG, Gürbüz M, Başoğlu T, Sezgin Göksu S, Buğdaycı Başal F, Türk HM, Özdemir Ö, Yeşil Çınkır H, Güven DC, Kuş T, Türker S, Koral L, Karakaş Y, Ak N, Paydaş S, Karcı E, Demiray AG, Demir A, Alan Ö, Keskin Ö, Nayır E, Tanrıverdi Ö, Yavuzşen T, Yumuk PF, Ateş Ö, Coşkun HŞ, Turhal S, Çay Şenler F. Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Eur J Cancer Care (Engl) 2020; 29:e13296. [PMID: 32864838 DOI: 10.1111/ecc.13296] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Revised: 07/16/2020] [Accepted: 08/07/2020] [Indexed: 02/06/2023]
Abstract
OBJECTIVE Fear of cancer recurrence (FCR) is an important psychological trauma associated with reduction in the quality of life, disruptions in the level of adjustment, emotional distress and anxiety. The purpose of the study was to evaluate the impact of patient-physician relationship on FCR. METHODS The study was designed as a multicentre survey study. The cancer survivors, who were under remission, were evaluated with structured questionnaires. Patient-physician relationship (PPR) scale in which higher scores indicate better relationship and FCR inventory was used. RESULTS Between January and April 2019, 1,580 patients were evaluated. The median age was 57.0 (19-88), and 66% were female. There was high level of FCR scores in 51% of participants. There was a negative correlation between PPR and FCR scores (r = -.134, p < .001). In multivariate analysis, young age, female gender, history of metastasectomy and worse PPR were associated with high levels of FCR. CONCLUSION It is the first data showing the adverse impact of worse PPR on FCR. The strategies to improve the PPR should be practised. In addition, the cancer survivors, who are under the risk of FCR, should be evaluated and managed.
Collapse
Affiliation(s)
- Ali Alkan
- Medical Oncology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey
| | - Arzu Yaşar
- Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
| | - Zeynep Gülsüm Güç
- Medical Oncology, Dokuz Eylül University School of Medicine, İzmir, Turkey
| | - Mustafa Gürbüz
- Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
| | - Tuğba Başoğlu
- Medical Oncology, Marmara University School of Medicine, İstanbul, Turkey
| | - Sema Sezgin Göksu
- Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Fatma Buğdaycı Başal
- Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Hacı Mehmet Türk
- Medical Oncology, Bezmialem Vakıf University School of Medicine, İstanbul, Turkey
| | - Özlem Özdemir
- Medical Oncology, İzmir Bozyaka Research and Training Hospital, İzmir, Turkey
| | - Havva Yeşil Çınkır
- Medical Oncology, Gaziantep University School of Medicine, Gaziantep, Turkey
| | - Deniz Can Güven
- Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey
| | - Tülay Kuş
- Medical Oncology, Dr Ersin Arslan Training and Research Hospital, Gaziantep, Turkey
| | - Sema Türker
- Medical Oncology, Dışkapı Yıldırım Beyazıt Research and Training Hospital, Ankara, Turkey
| | - Lokman Koral
- Medical Oncology, Çanakkale Onsekiz Mart University School of Medicine, Çanakkale, Turkey
| | - Yusuf Karakaş
- Medical Oncology, Bodrum Acıbadem Hospital, Muğla, Turkey
| | - Naziye Ak
- Department of Medical Oncology, Institute of Oncology, Istanbul University, İstanbul, Turkey
| | - Semra Paydaş
- Medical Oncology, Çukurova University School of Medicine, Adana, Turkey
| | - Ebru Karcı
- Medical Oncology, Bağcılar Research and Training Hospital, İstanbul, Turkey
| | | | - Atakan Demir
- Medical Oncology, Acıbadem Maslak Hospital, İstanbul, Turkey
| | - Özkan Alan
- Medical Oncology, Tekirdağ Public Hospital, Tekirdağ, Turkey
| | - Özge Keskin
- Medical Oncology, Selçuk University School of Medicine, Konya, Turkey
| | - Erdinç Nayır
- Medical Oncology, VM Medical Park Mersin Hospital, Mersin, Turkey
| | - Özgür Tanrıverdi
- Medical Oncology, Muğla Sıtkı Koçman University School of Medicine, Muğla, Turkey
| | - Tuğba Yavuzşen
- Medical Oncology, Dokuz Eylül University School of Medicine, İzmir, Turkey
| | | | - Öztürk Ateş
- Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital, Ankara, Turkey
| | - Hasan Şenol Coşkun
- Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Serdar Turhal
- Medical Oncology, Anadolu Medical Center, Kocaeli, Turkey
| | - Filiz Çay Şenler
- Medical Oncology, Ankara University School of Medicine, Ankara, Turkey
| |
Collapse
|
14
|
Peled N, Gillis R, Kilickap S, Froesch P, Orlov S, Filippova E, Demirci U, Christopoulos P, Cicin I, Basal FB, Yilmaz C, Fedor M, Korkmaz T, Paydas S, Gautschi O, Zirtiloglu A, Eralp Y, Cinkir HY, Sezer A, Erman M, Tural D, Turna H, Mazieres J, Dudnik E, Reguart N, Camidge DR, Ng TL, Şenler FÇ, Beypınar İ, Yazılıtaş D, Demirkazık A, Karaoğlu A, Okutur K, Coşkun HŞ, Şendur MAN, Isikdogan A, Cabuk D, Yumuk PF, Yıldız I, Kaplan MA, Özyılkan Ö, Öztop İ, Olmez OF, Aydin K, Aydıner A, Meydan N, Grinberg RD, Roisman LC. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. Lung Cancer 2020; 148:48-54. [PMID: 32799090 DOI: 10.1016/j.lungcan.2020.07.022] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Revised: 07/08/2020] [Accepted: 07/16/2020] [Indexed: 12/15/2022]
Abstract
Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1(+) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib. METHODS 123 patients were enrolled retrospectively (data cut-off 1/1/2019). Lorlatinib was administered through an early access program for patients with no other available therapy. Outcome and response were defined by each investigator upon RECIST 1.1 criteria. RESULTS 106 ALK(+) and 17 ROS1(+) patients recruited from 8 different countries. The ALK(+) cohort included 50 % males, 73 % never-smokers and 68 % with brain metastases. Extracranial (EC) and intracranial (IC) response rates (RR) were 60 % and 62 %, with disease control rates (DCR) of 91 % and 88 % respectively. Mean duration of therapy (DoT) was 23.9 ± 1.6 months and median overall survival (mOS) was 89.1 ± 19.6 months. ROS1 cohort enrolled 53 % males, 65 % never-smokers and 65 % had brain metastases. EC and IC RR were 62 % and 67 % with DCR of 92 % and 78 % respectively. Median DoT was 18.1 ± 2.5 months and mOS of 90.3 ± 24.4 months. OS and DoT in both cohorts were not significantly correlated with line of therapy nor other parameters. The most common adverse events of any grade were peripheral edema (48 %), hyperlipidemia (47 %), weight gain (25 %) and fatigue (30 %). CNS adverse events such as cognitive effect of grade 1-2 were reported in 18 % of patients. CONCLUSION Lorlatinib shows outstanding EC/IC efficacy in ALK/ROS1(+) NSCLC. The observed mOS of 89 ± 19 months in ALK(+) NSCLC supports previous reports, while mOS from of 90 ± 24 months is unprecedented for ROS1(+) NSCLC.
Collapse
Affiliation(s)
- Nir Peled
- The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel.
| | - Roni Gillis
- The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel
| | - Saadettin Kilickap
- Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
| | - Patrizia Froesch
- Oncology Institute of the Southern Switzerland, Bellinzona, Switzerland
| | - Sergei Orlov
- Pavlov First Saint Petersburg State Medical University, St Petersburg, Russia
| | - Elena Filippova
- Pavlov First Saint Petersburg State Medical University, St Petersburg, Russia
| | - Umut Demirci
- Uskudar University, Faculty of Medicine, Department of Medical Oncology, Turkey
| | - Petros Christopoulos
- Department of Thoracic Oncology, Thoraxklinik at Heidelberg University Hospital, and Translational Lung Research Heidelberg, Member of the German Center for Lung Research (DZL), Germany
| | - Irfan Cicin
- Trakya University, Faculty of Medicine, Department of Medical Oncology, Turkey
| | - Fatma Bugdayci Basal
- University of Health Sciences, Dr. A.Y. Ankara Oncology Hospital, Department of Medical Oncology, Turkey
| | - Cengiz Yilmaz
- Ege University, Faculty of Medicine, Department of Medical Oncology, İzmir, Turkey
| | - Moiseenko Fedor
- N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, 197798, Russian Federation; St. PetersburgClinical Research and Practical Center for Specialized Types of Medical Care (Oncologic), St. Petersburg, 197758, Russian Federation
| | - Taner Korkmaz
- Acibadem MAA University Hospital, School of Medicine, Department of Medical Oncology, Maslak Hospital, İstanbul, Turkey
| | - Semra Paydas
- Department of Oncology, Cukurova University Faculty of Medicine, Adana, Turkey
| | - Oliver Gautschi
- University of Berne and Cantonal Hospital of Lucerne, Switzerland
| | - Alisan Zirtiloglu
- Department of Medical Oncology, Bakirkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey
| | - Yesim Eralp
- Acibadem MAA University Hospital, School of Medicine, Department of Medical Oncology, Maslak Hospital, İstanbul, Turkey
| | - Havva Yesil Cinkir
- Gaziantep University, Faculty of Medicine, Department of Medical Oncology, Gaziantep, Turkey
| | - Ahmet Sezer
- Adana Baskent University, Faculty of Medicine, Department of Medical Oncology, Adana, Turkey
| | - Mustafa Erman
- Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Bakirkoy Sadi Konuk Training and Research Hospital, Istanbul, Turkey
| | - Hande Turna
- Cerrahpasa University, Faculty of Medicine Department of Medical Oncology, Istanbul, Turkey
| | - Julien Mazieres
- Centre Hospitalier Universitaire de Toulouse, Université Paul Sabatier, Toulouse, France
| | - Elizabeth Dudnik
- Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petah Tikva, 49100, Israel
| | - Noemi Reguart
- Division of Medical Oncology, Hospital Clínic, Barcelona,Spain; Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, Spain
| | - David Ross Camidge
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, 1665 North Aurora Court, Aurora, CO, 80045, USA
| | - Terry L Ng
- Ankara University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| | - Filiz Çay Şenler
- Department of Medical Oncology, Faculty of Medicine, Afyon Kocatepe University, Afyon, Turkey
| | - İsmail Beypınar
- Yildirim Beyazit University Faculty of Medicine, Department of Medical Oncology, Ankara, Turkey
| | - Doğan Yazılıtaş
- Dokuz Eylul University Faculty of Medicine, Department of Medical Oncology, Izmir, Turkey
| | - Ahmet Demirkazık
- Department of Medical Oncology, Faculty of Medicine, Afyon Kocatepe University, Afyon, Turkey
| | - Aziz Karaoğlu
- Medicalpark Bahçelievler Hospital, Department of Medical Oncology, Istanbul, Turkey
| | - Kerem Okutur
- Akdeniz University Faculty of Medicine, Department of Medical Oncology, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Dicle University Faculty of Medicine, Department of Medical Oncology, Diyarbakir, Turkey
| | | | - Abdurrahman Isikdogan
- Dicle University Faculty of Medicine, Department of Medical Oncology, Diyarbakir, Turkey
| | - Devrim Cabuk
- Kocaeli University, Division of Medical Oncology, Kocaeli, Turkey
| | - Perran Fulden Yumuk
- Marmara University Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
| | - Ibrahim Yıldız
- Acibadem MAA University Hospital, School of Medicine, Department of Medical Oncology, Maslak Hospital, İstanbul, Turkey
| | - M Ali Kaplan
- Dicle University Faculty of Medicine, Department of Medical Oncology, Diyarbakir, Turkey
| | - Özgür Özyılkan
- Adana Baskent University, Faculty of Medicine, Department of Medical Oncology, Adana, Turkey
| | - İlhan Öztop
- Medicalpark Bahçelievler Hospital, Department of Medical Oncology, Istanbul, Turkey
| | - Omer Fatih Olmez
- Medipol University Faculty of Medicine, Department of Medical Oncology, Istanbul, Turkey
| | | | - Adnan Aydıner
- Istanbul University Institute of Cancer, Department of Medical Oncology, Istanbul, Turkey
| | - Nezih Meydan
- Adnan Menderes Univesity Faculty of Medicine, Turkey
| | - Roxana Denisa Grinberg
- The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel
| | - Laila C Roisman
- The Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka Medical Center, Beer-Sheva, Israel; Faculty of Health Sciences, Ben-Gurion University, Beer-Sheva, Israel
| |
Collapse
|
15
|
Uçar MA, Arikan F, Coşkun HŞ, Kondak Y, Tatlı AM, Göksu SS. Correction to: Fertility in testicular cancer patients: a single‑centre study in Turkey. Int J Clin Oncol 2019; 25:501. [PMID: 31797189 DOI: 10.1007/s10147-019-01572-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
The updated version of Table 4 of original publication and the Compliance with ethical standards are given in this correction.
Collapse
Affiliation(s)
- Mürvet Artuk Uçar
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Fatma Arikan
- Faculty of Nursing, Akdeniz University, Antalya, Turkey.
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Yasemin Kondak
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Ali Murat Tatlı
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Sema Sezgin Göksu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
16
|
Uçar MA, Arikan F, Coşkun HŞ, Kondak Y, Tatlı AM, Göksu SS. Fertility in testicular cancer patients: a single-centre study in Turkey. Int J Clin Oncol 2019; 25:495-500. [DOI: 10.1007/s10147-019-01534-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2019] [Accepted: 08/21/2019] [Indexed: 12/14/2022]
|
17
|
Artaç M, Korkmaz L, Coşkun HŞ, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan NF, Doruk H, Avcı N, Turhal NS. Bevacuzimab May Be Less Effective in Obese Metastatic Colorectal Cancer Patients. J Gastrointest Cancer 2019; 50:214-220. [PMID: 29302856 DOI: 10.1007/s12029-017-0047-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
PURPOSE The purpose of this study was to investigate whether obesity affects survival in metastatic colorectal cancer (mCRC) patients treated with bevacizumab combined with chemotherapy. METHODS A total of 563 patients with mCRC who had received first-line chemotherapy in combination with bevacizumab were studied. Patients were grouped as obese (BMI levels > 30) or non-obese (BMI levels < 30). Progression-free survival (PFS) and overall survival (OS) were analyzed. Primary tumor location was also investigated in terms of PFS and OS. RESULTS The median age of the patients was 59 years. The non-obese group had longer PFS than the obese group (P = 0.030). The 2-year survival rate of the non-obese group was also significantly higher (P = 0.036). The median PFS of non-obese patients was significantly longer in Kras wild-type patients (10.1 vs. 8.1 months, P = 0.010). Among patients with left-sided primary tumor location, median PFS and OS were significantly higher in the non-obese group (PFS non-obese, 11.5 months; obese, 8.8 months; P = 0.002) (OS non-obese, 29.4 months; obese, 21.4 months; P = 0.026). CONCLUSIONS Efficacy of bevacizumab may be lower in obese patients. Among patients with Kras wild-type left-sided tumors treated with bevacizumab-based regimens, the prognosis could be worse for obese patients than that for non-obese patients. There is a need for prospectively designed studies of obese patients to prove the efficacy and dosages of bevacizumab in treatment of mCRC.
Collapse
Affiliation(s)
- Mehmet Artaç
- Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, 42080, Konya, Turkey.
| | - Levent Korkmaz
- Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, 42080, Konya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Faculty of Medicine, Akdeniz University, Antalya, Turkey
| | - Faysal Dane
- Department of Medical Oncology, Faculty of Medicine, Marmara University, Istanbul, Turkey
| | - Bülent Karabulut
- Department of Medical Oncology, Faculty of Medicine, Ege University, Izmir, Turkey
| | - Mustafa Karaağaç
- Department of Medical Oncology, Meram Faculty of Medicine, Necmettin Erbakan University, 42080, Konya, Turkey
| | - Devrim Çabuk
- Department of Medical Oncology, Faculty of Medicine, Kocaeli University, Kocaeli, Turkey
| | - Senem Karabulut
- Department of Medical Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
| | - Nuri Faruk Aykan
- Department of Medical Oncology, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey
| | - Hatice Doruk
- Department of Medical Oncology, Acıbadem Bursa Hospital, Bursa, Turkey
| | - Nilüfer Avcı
- Department of Medical Oncology, Ali Osman Sönmez Oncology Hospital, Bursa, Turkey
| | | |
Collapse
|
18
|
Arıkan F, Uçar MA, Kondak Y, Tekeli A, Kartöz F, Özcan K, Göksu SS, Coşkun HŞ. Reasons for complementary therapy use by cancer patients, information sources and communication with health professionals. Complement Ther Med 2019; 44:157-161. [PMID: 31126549 DOI: 10.1016/j.ctim.2019.03.017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2018] [Revised: 02/21/2019] [Accepted: 03/25/2019] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Cancer patients are known to commonly use complementary therapies (CT). However, it is emphasized that patients do not share sufficient information with health professionals about this subject and that the subject is ignored in oncology practice. The aim of the study is to assess cancer patients' reasons for using complementary therapy, information resources and communication with health professionals. METHODS The study is a descriptive, cross-sectional study. In this study, a questionnaire was used by the researchers. A questionnaire form consisting of 3 parts was used. In the first part of this form, there were questions about the gender, age and educational status of the patients (8 questions). In the second part, there were questions about disease and treatment information (3 questions), and the third part had questions about the use of complementary therapies (9 questions). To determine the use of complementary therapy, patients were asked 'Do you currently use complementary treatment?' (Yes or No). 183 patients included in the study completed the questionnaire about complementary therapies. RESULTS In this study, it was determined that 37.7% of the patients were using complementary therapies. The most commonly used complementary therapy was natural products (46.4%). The most common reason for using complementary therapy was to provide support for treatment. Almost half of the cancer patients (48.5%) did not talk about this issue with their physicians, and 41.1% of them did not talk about CT with their nurses. The study found that the most important reason why the patients did not talk about CT was that they were not asked about it by health professionals. CONCLUSION This study determined that almost half of patients could not receive information about CT from health professionals. Patients expect physicians and nurses to initiate communication on this subject. Providing healthcare professionals with evidence-based counseling about CT is essential for improving patient safety and patient outcomes.
Collapse
Affiliation(s)
- Fatma Arıkan
- Akdeniz University, Faculty of Nursing, Antalya, Turkey.
| | - Mürvet Artuk Uçar
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Yasemin Kondak
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Aysel Tekeli
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Funda Kartöz
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Keziban Özcan
- Department of Medical Oncology, Akdeniz Universty Hospital, Antalya, Turkey
| | - Sema Sezgin Göksu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
19
|
Musri FY, Mutlu H, Eryilmaz MK, Salim DK, Tazegul G, Coşkun HŞ. Hypercalcemia associated with squamous cell carcinoma of renal pelvis: A case and review of the literature. J Cancer Res Ther 2019; 15:S170-S172. [PMID: 30900642 DOI: 10.4103/0973-1482.187236] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Renal pelvis squamous cell carcinoma (RSCC) is a rare tumor. It starts with nonspecific symptoms and it is usually at an advanced stage with a poor prognosis at the time of diagnosis. SCC-associated hypercalcemia is a well-known paraneoplastic syndrome; however RSCC-associated hypercalcemia is a rare condition. Our patient is a 57-year-old-male patient with no bone metastases. Based on the literature screening on PubMed Database for paraneoplastic malignant hypercalcemia-associated RSCC, we found a few cases.
Collapse
Affiliation(s)
- Fatma Yalcin Musri
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Mutlu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | | | - Derya Kivrak Salim
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Gokhan Tazegul
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
20
|
Eryilmaz MK, Mutlu H, Ünal B, Salim DK, Musri FY, Coşkun HŞ. The importance of stromal and intratumoral tumor lymphocyte infiltration for pathologic complete response in patients with locally advanced breast cancer. J Cancer Res Ther 2018; 14:619-624. [PMID: 29893329 DOI: 10.4103/0973-1482.174550] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Objective Increased tumor-infiltrating lymphocytes (TILs) in breast carcinoma tissues is an independent predictive factor for pathologic complete response (pCR). The increased intratumoral and stromal TILs (sTILs) in breast cancer (BC) have significant prognostic effects. In this study, we evaluated whether pCR rates to neoadjuvant chemotherapy (NACT) are higher in tumors with increased number of TILs in the pretreatment biopsy. Materials and Methods We retrospectively evaluated the number of TILs in intratumoral TILs (iTILs) and sTILs compartments from pretreatment full-face hematoxylin and eosin-stained sections of 62 patients with locally advanced BC (LABC) who received NACT. The capacity of sTILs and iTILs in predicting pCR to NACT in LABC analyzed using receiver operating characteristic (ROC) curve analysis. Results According to ROC curve analysis, the optimum sTILs and iTILs cut-off points (the number of positive cells per square millimeter of tissue) for patients with LABC patients with pCR (+) were 19 (area under the curve (AUC): 0.668, 95% confidence interval [CI] [0.501-0.835],P = 0.064) and 4 (AUC: 0.786, 95%CI [0.666-0.907],P = 0.002), respectively. Of the 62 patients, 26 had sTILs >19 and 25 had iTILs >4. The patients were divided into two according to percent of sTILs (sTILs >19 and sTILs ≤19 groups) and iTILs (iTILs >4 and iTILs ≤4 groups). Both sTILs >19 and iTILs >4 patients were associated with development higher pCR. While pCR was significantly higher in iTILs >4 patients (P = 0.002), it was not significantly in sTILs >19 patients (P = 0.107). Conclusions There is significantly an association between pCR and increased number of intratumoral TILs (>4 cells/mm 2 of tissue) in BC who received NACT.
Collapse
Affiliation(s)
- Melek Karakurt Eryilmaz
- Department of Medical Oncology, School of Medicine, Akdeniz University, Konyaalti, Antalya 07070, Turkey
| | - Hasan Mutlu
- Department of Medical Oncology, School of Medicine, Akdeniz University, Konyaalti, Antalya 07070, Turkey
| | - Betül Ünal
- Department of Pathology, School of Medicine, Akdeniz University, Konyaalti, Antalya 07070, Turkey
| | - Derya Kıvrak Salim
- Department of Medical Oncology, School of Medicine, Akdeniz University, Konyaalti, Antalya 07070, Turkey
| | - Fatma Yalçın Musri
- Department of Medical Oncology, School of Medicine, Akdeniz University, Konyaalti, Antalya 07070, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, School of Medicine, Akdeniz University, Konyaalti, Antalya 07070, Turkey
| |
Collapse
|
21
|
Korkmaz L, Coşkun HŞ, Dane F, Karabulut B, Karaağaç M, Çabuk D, Karabulut S, Aykan NF, Doruk H, Avcı N, Turhal NS, Artaç M. Kras-mutation influences outcomes for palliative primary tumor resection in advanced colorectal cancer-a Turkish Oncology Group study. Surg Oncol 2018; 27:485-489. [PMID: 30217306 DOI: 10.1016/j.suronc.2018.05.032] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 05/28/2018] [Accepted: 05/29/2018] [Indexed: 02/05/2023]
Abstract
PURPOSE We aimed to investigate the prognostic effect of primary tumor resection (PTR) prior to bevacizumab-based treatments in unresectable metastatic colorectal cancer (mCRC). METHODS We retrospectively collected 341 mCRC cases with unresectable metastases at diagnosis. PTR was performed in 210 cases (the surgery group) and the other patients (n = 131) were followed without PTR (the no-surgery group). All the patients were treated with bevacizumab combined chemotherapy regimens. RESULTS The median progression free survival (PFS) of the surgery group was 10.4 months (95% CI: 8.9-11.9), which was significantly better than that of the no-surgery group (7.6 months, 95% CI: 6.4-8.8, P=0.000). The median overall survival (OS) of the surgery group was longer than that of the no-surgery group (27.4 months vs. 18.3 months, respectively, P=0.000). The median PFS and OS of the surgery group were 10.4 months and 28.2 months, which were significantly longer than that of the no-surgery group in Kras-mutant patients (7.8 months and 18.3 months; P=0.004, P=0.028, respectively). There was no difference in terms of PFS and OS between the surgery and the no-surgery groups in Kras-wild type patients. CONCLUSION Palliative PTR may improve the survival outcomes for unresectable mCRC patients. PTR may be preferred, particularly in Kras-mutant patients.
Collapse
Affiliation(s)
- Levent Korkmaz
- Department of Medical Oncology, NecmettinErbakan University, Meram Faculty of Medicine, Konya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - Faysal Dane
- Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey
| | - Bülent Karabulut
- Department of Medical Oncology, Ege University Faculty of Medicine, Izmir, Turkey
| | - Mustafa Karaağaç
- Department of Medical Oncology, NecmettinErbakan University, Meram Faculty of Medicine, Konya, Turkey
| | - Devrim Çabuk
- Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Senem Karabulut
- Department of Medical Oncology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
| | - Nuri Faruk Aykan
- Department of Medical Oncology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
| | - Hatice Doruk
- Department of Medical Oncology, Acıbadem Bursa Hospital, Bursa, Turkey
| | - Nilüfer Avcı
- Department of Medical Oncology, Ali Osman Sönmez Oncology Hospital, Bursa, Turkey
| | | | - Mehmet Artaç
- Department of Medical Oncology, NecmettinErbakan University, Meram Faculty of Medicine, Konya, Turkey.
| |
Collapse
|
22
|
Eryilmaz MK, Mutlu H, Tazegul G, Eryılmaz R, Müsri FY, Salim DK, Ünal B, Coşkun HŞ. Multiple pelvic cysts in a patient with familial Mediterranean fever: Benign cystic mesothelioma. J Cancer Res Ther 2018; 13:1047-1049. [PMID: 29237974 DOI: 10.4103/jcrt.jcrt_125_16] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Benign cystic mesothelioma (BCM) is a rare tumor arising from endothelial cells of the pelvic visceral or parietal peritoneum. It is a clinically and histopathologically benign disease. Etiology and pathogenesis of BCM remain unclear. Familial Mediterranean fever (FMF) is an inherited disorder characterized by episodes of fever, and abdominal, chest and/or joint inflammation. Association between malignant mesothelioma and FMF has been reported previously; however, co-existence of FMF and BCM is rare. Here, we report a case of BCM in a 43-year-old male patient with FMF.
Collapse
Affiliation(s)
| | - Hasan Mutlu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Gokhan Tazegul
- Department of Internal Medicine, Akdeniz University School of Medicine, Antalya, Turkey
| | - Ramazan Eryılmaz
- Department of General Surgery, Akdeniz University School of Medicine, Antalya, Turkey
| | - Fatma Yalçın Müsri
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Derya Kıvrak Salim
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Betül Ünal
- Department of Pathology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
23
|
Mutlu H, Salim DK, Gündüz Ş, Eryılmaz MK, Musri FY, Coşkun HŞ. Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard? J Cancer Res Ther 2017; 13:510-513. [PMID: 28862218 DOI: 10.4103/0973-1482.161933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND The prognosis of recurrent or metastatic head and neck squamous cell cancer (HNSCC) is very poor. In the present retrospective study, we compared the impact of docetaxel plus cisplatin plus fluorouracil (TCF), and cisplatin plus fluorouracil plus cetuximab (CF-Ctx) regimens on the prognosis of patients with recurrent or metastatic HNSCC in first-line. MATERIALS AND METHODS A total of 70 patients were evaluated as two groups, according to treatment protocol: TCF (n: 47) and CF-Ctx (n: 23). The groups were compared regarding survival. RESULTS The median progression-free survival was 7.3 and 8.3 months, TCF and CF-Ctx groups, respectively, (P = 0.280). The median overall survival (OS) was 15.6 and 9.3 months for TCF and CF-Ctx groups, respectively, (P = 0.029). The dose reduction and using of granulocyte colony stimulating factor were significantly higher in TCF group (P = 0.048 and P = 0.018, respectively). CONCLUSION In first-line setting, TCF regimen is superior to CF-Ctx regimen in terms of OS in patients with recurrent or metastatic HNSCC, who did not previously receive neoadjuvant or adjuvant chemotherapy.
Collapse
Affiliation(s)
- Hasan Mutlu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Derya Kıvrak Salim
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Şeyda Gündüz
- Department of Antalya Research and Training Hospital, Antalya, Turkey
| | | | - Fatma Yalçın Musri
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
24
|
Müsri FY, Mutlu H, Eryılmaz MK, Salim DK, Coşkun HŞ. Experience of bevacizumab in a patient with colorectal cancer after renal transplantation. J Cancer Res Ther 2016; 11:1018-20. [PMID: 26881574 DOI: 10.4103/0973-1482.168996] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Bevacizumab is a drug that is widely used for the first-line treatment of metastatic colorectal cancer (mCRC). Bevacizumab neutralizes vascular endothelial growth factor and can lead to proteinuria and renal damage. In this case, experience on full dose short-time treatment of bevacizumab in a patient under immunosuppressive treatment for renal transplantation with chronic renal failure has been shared. The patients were diagnosed with mCRC 7 months ago. The patient had multiple liver metastases at the time of the diagnosis. He had a history of renal transplantation 2 years ago because of renal failure, and he had been under immunosuppressive treatment for this reason. 5-fluorouracil-leucovorin-irinotecan -bevacizumab regimen was begun for the treatment of mCRC. The dose of bevacizumab was 5 mg/kg/day for 14 days. There was 2.5 g/day of proteinuria at the start of the treatment. However, renal dysfunction progressed, and proteinuria increased to 4 g/day in the 3rd month of treatment. In this case, the experience of using bevacizumab in a patient under immunosuppressive treatment for renal transplantation with chronic failure has been presented.
Collapse
Affiliation(s)
- Fatma Yalcin Müsri
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | | | | | | | | |
Collapse
|
25
|
Artaç M, Coşkun HŞ, Dane F, Karabulut B, Korkmaz L, Karaağaç M, Çabuk D, Karabulut S, Faruk Aykan N, Doruk H, Avcı N, Turhal NS. Benefit of Bevacizumab-Based Frontline Therapy in Patients with Metastatic Colorectal Cancer (mCRC): a Turkish Oncology Group Study. J Gastrointest Cancer 2016; 47:264-72. [PMID: 27126591 DOI: 10.1007/s12029-016-9823-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
BACKGROUND Several chemotherapy regimens using bevacizumab have been developed. Our goal was to investigate regimens that have demonstrated significant clinical activity in patients with metastatic colorectal cancer (mCRC). MATERIALS AND METHODS Six hundred and sixty six patients with mCRC who received first-line chemotherapy combination with bevacizumab were studied. Fluoropyrimidine (F) plus irinotecan (I)-based (FI-bev), F plus oxaliplatin (O)-based (FO-bev), and F-based (F-bev) treatment regimens were compared with respect to progression-free survival (PFS) and overall survival (OS). RESULTS The median PFS of FI-bev (n = 414) was 10.9 months (95 % CI 10-11.8), of FO-bev (n = 211) was 9.4 months (95 % CI 8.3-10.4), and of F-bev (n = 41) was 9.5 months (95 % CI 5.9-13.1) (p = 0.089). The median OS of FI-bev was 26.3 months (95 % CI 21.7-30.9), of FO-bev was 27 months (95 % CI 24.3-29.7), and of F-bev was 23.3 months (95 % CI 12.7-33.9) (p = 0.102). In KRAS wild-type patients, the median PFS of FI-bev group was significantly longer than FO-bev group (10.5 vs. 9.1 months, p = 0.006). The FI-bev group had better OS than FO-bev group with borderline significance (p = 0.058). The FI-bev group had significantly longer OS than F-bev group. Patients who underwent metastasectomy or those with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 had longer PFS and OS independent of the type of chemotherapy regimen. CONCLUSION FI-bev may be the preferred frontline regimen for patients with KRAS wild-type mCRC. Metastasectomy and performance score were the strongest positive predictors of OS and PFS regardless of backbone chemotherapy regimen.
Collapse
Affiliation(s)
- Mehmet Artaç
- Department of Medical Oncology, Necmettin Erbakan University, Meram Medical Faculty, 42080, Konya, Turkey.
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University Faculty of Medicine, Antalya, Turkey
| | - Faysal Dane
- Department of Medical Oncology, Marmara University Faculty of Medicine, Istanbul, Turkey
| | - Bülent Karabulut
- Department of Medical Oncology, Ege University Faculty of Medicine, Izmir, Turkey
| | - Levent Korkmaz
- Department of Medical Oncology, Necmettin Erbakan University, Meram Medical Faculty, 42080, Konya, Turkey
| | - Mustafa Karaağaç
- Department of Medical Oncology, Necmettin Erbakan University, Meram Medical Faculty, 42080, Konya, Turkey
| | - Devrim Çabuk
- Department of Medical Oncology, Kocaeli University Faculty of Medicine, Kocaeli, Turkey
| | - Senem Karabulut
- Department of Medical Oncology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
| | - Nuri Faruk Aykan
- Department of Medical Oncology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
| | - Hatice Doruk
- Department of Medical Oncology, Acıbadem Bursa Hospital, Bursa, Turkey
| | - Nilüfer Avcı
- Department of Medical Oncology, Ali Osman Sönmez Oncology Hospital, Bursa, Turkey
| | | |
Collapse
|
26
|
Merdin A, Merdin FA, Gündüz Ş, Bozcuk H, Coşkun HŞ. Opioid endocrinopathy: A clinical problem in patients with cancer pain. Exp Ther Med 2016; 11:1819-1822. [PMID: 27168810 DOI: 10.3892/etm.2016.3156] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2014] [Accepted: 11/25/2015] [Indexed: 11/05/2022] Open
Abstract
Opioids are commonly used in cancer pain management. The present study aimed to investigate the occurrence of endocrine dysfunction in patients with cancer pain treated with opioids. The study included 20 patients with cancer-associated pain. All data were obtained from malignant tumors diagnosed and followed up at the Oncology Clinic of Akdeniz University Hospital (Akdeniz, Turkey) between May 2009 and December 2013. Serum samples were collected to determine the levels of hypophyseal, gonadal and thyroid hormones. The inclusion criteria for the study were as follows: Chronic cancer pain, daily treatment with a morphine equivalent daily dose (MEDD) of ≥25 mg/dl for ≥1 month, and a visual analog score of <2. All independent predictors were evaluated using logistic regression analysis. The results did not demonstrate any significant association between MEDD and gender, or the levels of adrenocorticotropic hormone, cortisol, prolactin, thyroid-stimulating hormone, free thyroxine, follicle-stimulating hormone and luteinizing hormone. However, the levels of testosterone (P=0.040) and of free testosterone (P=0.041) were significantly affected by the MEDD. Conversely, prolactin levels were demonstrated to significantly increase with MEDD (P=0.083). The results also indicated that the required opioid analgesic dose and MEDD were significantly affected by age (P≤0.001). Opioid therapy in patients with cancer may inhibit gonadal function and cause hyperprolactinemia.
Collapse
Affiliation(s)
- Alparslan Merdin
- Department of Internal Medicine, Akdeniz University Hospital, Antalya 07058, Turkey
| | - Fatma Avci Merdin
- Department of Internal Medicine, Akdeniz University Hospital, Antalya 07058, Turkey
| | - Şeyda Gündüz
- Department of Medical Oncology, Antalya Education and Research Hospital, Antalya 07070, Turkey
| | - Hakan Bozcuk
- Department of Internal Medicine, Division of Oncology, Akdeniz University Hospital, Antalya 07058, Turkey
| | - Hasan Şenol Coşkun
- Department of Internal Medicine, Division of Oncology, Akdeniz University Hospital, Antalya 07058, Turkey
| |
Collapse
|
27
|
Mutlu H, Balkarlı H, Musri FY, Salim DK, Eryılmaz MK, Ünal B, Coşkun HŞ. Gastrointestinal stromal tumor and isolated anterior tibial muscle metastasis as first recurrence. J Cancer Res Ther 2016; 11:1037. [PMID: 26881647 DOI: 10.4103/0973-1482.151862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
In the presented case, we report gastrointestinal stromal tumor (GIST) in a patient using adjuvant imatinib in whom isolated metastasis to anterior tibial muscle as first recurrence was diagnosed. A 66-year-old woman was diagnosed with GIST on October 2012 and was followed up with adjuvant imatinib until June 2014. In this time, there was a nodular and fixed lesion with 1.5-2 cm of diameter in right lateral pre-tibial area. The lesion was resected, and it was reported as GIST metastasis by pathologist. GIST metastasis to muscle under knee is a generally unexpected area for any tumor metastasis. In modern treatment era, due to the increasing survival of the patients with GIST using targeted therapy, the metastatic pattern and behavior of GIST may be changing.
Collapse
Affiliation(s)
| | - Hüseyin Balkarlı
- Department of Orthopedia, Akdeniz University School of Medicine, Antalya, Turkey
| | | | | | | | | | | |
Collapse
|
28
|
Mutlu H, Arslan D, Gündüz Ş, Tural D, Büyükçelik A, Benderli Cihan Y, Aslan T, Bozcuk H, Şenol Coşkun H. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. Chemotherapy 2015; 60:107-111. [PMID: 25721008 DOI: 10.1159/000371414] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2014] [Accepted: 12/08/2014] [Indexed: 11/19/2022]
Abstract
BACKGROUND Stage IIIB non-small cell lung cancer (NSCLC) consists of T4N2M0 and TXN3M0 NSCLC. In the present study, we aimed to evaluate the efficacy of different treatment strategies on the survival of patients with radiologically confirmed T4N2M0 NSCLC. METHODS A total of 145 patients were evaluated in three groups according to the treatment protocol: induction chemotherapy followed by chemoradiotherapy (induction group); chemoradiotherapy (CRT group), and chemoradiotherapy followed by consolidation chemotherapy (consolidation group). The groups were compared regarding survival. RESULTS The median progression-free survival (PFS) was 10.9, 10.8 and 17.1 months for the induction, CRT and consolidation groups, respectively (p = 0.021). The median overall survival (OS) was 17.6, 13.8 and 25.2 months for the induction, CRT and consolidation groups, respectively (p = 0.001). CONCLUSIONS The patients with T4N2M0 NSCLC who were treated with chemoradiotherapy followed by consolidation chemotherapy had the best outcome in terms of PFS and OS.
Collapse
|
29
|
Eryılmaz MK, Mutlu H, Salim DK, Musri FY, Coşkun HŞ. Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. J Oncol Pharm Pract 2015; 22:806-810. [PMID: 26467267 DOI: 10.1177/1078155215611048] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Abstract
Posterior reversible leukoencephalopathy syndrome (PRES) is a syndrome characterized by headache, hypertension, confusion, visual disturbance, and seizures accompanied by subcortical vasogenic edema, predominantly involving the parietal and occipital lobes. The syndrome is usually described in malignant hypertension, eclampsia, renal failure, immunosuppressive, and cytotoxic chemotherapies. Bevacizumab, a monoclonal antibody that binds to the vascular endothelial growth factor (VEGF) has been linked to PRES. We carried out review of reports documenting the occurrence of PRES in patients receiving bevacizumab. This literature review was conducted by utilizing PubMed Database. If early diagnosed, PRES is reversible. We present a case of fatal PRES-associated coma induced by bevacizumab in metastatic colorectal cancer.
Collapse
Affiliation(s)
| | - Hasan Mutlu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Derya Kıvrak Salim
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Fatma Yalçın Musri
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
30
|
Yalçin A, Silay K, Büyükçelik A, Işikdoğan A, Türk HM, Coşkun HŞ, Özdemir F, Uğurlu M, Üstü Y, Yalçin B. Opinions of the Turkish population on cancer and being informed of the diagnosis of cancer. Turk J Med Sci 2015; 45:387-92. [PMID: 26084131 DOI: 10.3906/sag-1312-72] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
BACKGROUND/AIM An opinion survey was conducted to investigate the opinions and attitudes of the Turkish population regarding cancer if they or one of their family members were to receive a diagnosis of cancer. MATERIALS AND METHODS The opinion survey was completed by 6566 subjects and consisted of questions about the demographics of the participants and their overall opinions about cancer. The other points of the investigation asked whether they would inform relatives who had cancer about the diagnosis and whether they would prefer to be informed if they were the one with the cancer diagnosis. RESULTS The median age of the participants was 33 years (range: 18-100) and 53.3% were male. It was found that 57.7% of the participants would prefer not to disclose a cancer diagnosis to their first-degree relatives. The diagnosis had been disclosed to relatives with cancer in 69.9% of cases. When asked about their overall opinion of cancer management, 76.5% of participants were optimistic, 16.3% were pessimistic, and 2.9% had mixed opinions. CONCLUSION This study represents one of the largest surveys done in Turkey to identify the thoughts of healthy people about cancer and their opinion on informing their relatives about the diagnosis if the relatives have cancer. It is comparable with reports from East Europe and Asian countries.
Collapse
|
31
|
Eryılmaz MK, Mutlu H, Salim DK, Musri FY, Tural D, Başsorgun I, Coşkun HŞ. Ipilimumab may increase the severity of cutenaous toxicity related to radiotherapy. J Oncol Pharm Pract 2015; 22:533-6. [DOI: 10.1177/1078155215572930] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Ipilimumab, monoclonal antibody against cytotoxic T-lymphocyte antigen-4 and, radiotherapy are commonly used to treat unresectable and metastatic melanoma. As a result of upregulation of immune system with ipilimumab, many immune-related adverse effects, such as dermatitis, colitis, hepatitis, and hypophysitis, have been previously reported in literature. Typically, these effects are treated with high-dose steroids and mostly heal up. Here, we report a case who was receiving radiotherapy due to metastatic malignant melanoma with atypical generalized rash, which was enlarged with concurrent ipilimumab treatment.
Collapse
Affiliation(s)
| | - Hasan Mutlu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Derya Kıvrak Salim
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Fatma Yalçın Musri
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Ibrahim Başsorgun
- Department of Pathology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
32
|
Urun Y, Utkan G, Cangir AK, Oksuzoglu OB, Ozdemir N, Oztuna DG, Kocaman G, Coşkun HŞ, Kaplan MA, Yuksel C, Demirkazik A, Icli F. Association of ABO blood group and risk of lung cancer in a multicenter study in Turkey. Asian Pac J Cancer Prev 2015; 14:2801-3. [PMID: 23803034 DOI: 10.7314/apjcp.2013.14.5.2801] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The ABO blood groups and Rh factor may affect the risk of lung cancer. MATERIALS AND METHODS We analyzed 2,044 lung cancer patients with serologically confirmed ABO/Rh blood group. A group of 3,022,883 healthy blood donors of Turkish Red Crescent was identified as a control group. We compared the distributions of ABO/Rh blood group between them. RESULTS The median age was 62 years (range: 17-90). There was a clear male predominance (84% vs. 16%). Overall distributions of ABO blood groups were significantly different between patients and controls (p=0.01). There were also significant differences between patients and controls with respect to Rh positive vs. Rh negative (p=0.04) and O vs. non-O (p=0.002). There were no statistically significant differences of blood groups with respect to sex, age, or histology. CONCLUSIONS In the study population, ABO blood types were associated with the lung cancer. Having non-O blood type and Rh-negative feature increased the risk of lung cancer. However, further prospective studies are necessary to define the mechanisms by which ABO blood type may influence the lung cancer risk.
Collapse
Affiliation(s)
- Yuksel Urun
- Department of Medical Oncology, Ankara University School of Medicine, Turkey.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Musri FY, Mutlu H, Kıvrak Salim D, Karakurt Eryılmaz M, Ünal B, Tural D, Şenol Coşkun H. Sorafenib-induced severe urticaria in a patient with hepatocellular cancer. J Oncol Pharm Pract 2015; 22:350-3. [DOI: 10.1177/1078155214565126] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Sorafenib which is used in the treatment of renal, thyroid and hepatocellular cancers is a multi-targeted tyrosine kinase inhibitor. Though sorafenib is associated with some side effects, it is known that sorafenib is generally well tolerated compared to other tyrosine kinase inhibitors. In the present case, hepatocellular cancer was diagnosed seven months ago. The disease was in stage IIIB at the time of diagnosis. Sorafenib was initiated with a dose of 400 mg twice daily because of disease progression after two cycles of doxorubicin. The reactions on the skin of the arms and the body of the patient occurred in the eighth week of treatment. Skin biopsy was performed and urticaria was diagnosed after pathologic examination. No other disorders or drugs which may cause urticaria were detected in the patient. Skin reactions disappeared one week after sorafenib discontinuation without any further intervention.
Collapse
Affiliation(s)
- Fatma Yalçın Musri
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Mutlu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Derya Kıvrak Salim
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | | | - Betül Ünal
- Department of Pathology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
34
|
Kivrak Salim D, Mutlu H, Karakurt Eryilmaz M, Yalçin Musri F, Tural D, Coşkun HŞ. Metronomic maintenance chemotherapy in patients presenting with paraneoplastic autoimmune hepatitis with recurrent thymic carcinoma. J Oncol Pharm Pract 2014; 22:313-5. [DOI: 10.1177/1078155214551318] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Autoimmune hepatitis is a rarely seen autoimmune paraneoplastic syndrome of thymic carcinoma. Chemotherapy may be an effective choice in the treatment of primary tumor and paraneoplastic disorder. In this case, we report a 32-year-old man presented with increased liver enzymes and cholestasis with a history of thymoma surgically removed four years ago. Liver biopsy showed chronic active autoimmune hepatitis. Computed tomography scan showed pulmonary metastases and pleural mass as a recurrence of thymic carcinoma, proven by biopsy. After four cycles of cisplatin plus adriamycin plus cyclophosphamide plus vincristine and six cycles of paclitaxel plus gemcitabine, maintenance metronomic cyclophosphamide plus etoposide regimen was offered to the patient. Complete biological signs of hepatitis without need for steroids or immune suppressors and complete radiologic response in primary tumor were achieved. Maintenance metronomic chemotherapy regimens may be an alternative to the current treatment options in patients with thymic carcinomas.
Collapse
Affiliation(s)
- Derya Kivrak Salim
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Mutlu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | | | - Fatma Yalçin Musri
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
35
|
Tatlı AM, Coşkun HŞ, Uysal M, Arslan D, Sezgin Göksu S, Güenay Gündüz Ş, Çakal S, Bozcuk HŞ, Savaş B. Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma. Int J Clin Exp Med 2014; 7:2191-2196. [PMID: 25232406 PMCID: PMC4161566] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2014] [Accepted: 07/11/2014] [Indexed: 06/03/2023]
Abstract
Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor, and it has been found to increase both progression-free survival and overall survival when it is combined with chemotherapeutic agents in the first-line and subsequent treatment of metastatic colorectal carcinoma. The objective of this study was to show the efficacy of maintenance treatment with capecitabine plus bevacizumab in patients with metastatic colorectal cancer who responded to treatment with FOLFIRI plus bevacizumab. The study included patients with metastatic colorectal cancer who received FOLFIRI plus bevacizumab as a first-line treatment. Patients who had objective response with FOLFIRI plus bevacizumab treatment after an average period of 6 months received a maintenance treatment with capecitabine plus bevacizumab (capecitabine 2 x 1000 mg/m(2), 1 - 14 days, every 21 days, bevacizumab 7.5 mg/m(2), every 21 days) until disease progression or toxicity. The time to progression on bevacizumab treatment was evaluated. A total of 29 patients (15 male, 14 female) were included. The mean age was 62 years. The mean number of cycles for maintenance treatment with capecitabine plus bevacizumab was 12. The median PFS was 16 ± 3 months, and OS was 42 ± 11 months. PFS and OS were remarkably higher in patients with a complete or near complete response to induction treatment. Fourteen patients (48%) experienced hand-foot syndrome associated with capecitabine plus bevacizumab treatment, without any severe toxicity. Inselected patients with metastatic colorectal carcinoma who had a remarkable objective response to FOLFIRI plus bevacizumab treatment, a maintenance treatment with capecitabine plus bevacizumab following FOLFIRI plus bevacizumab until disease progression may be a suitable, effective and tolerable regimen, which requires further studies.
Collapse
Affiliation(s)
- Ali Murat Tatlı
- Department of Medical Oncology, Van Training and Research HospitalVan, Turkey
| | | | - Mükremin Uysal
- Department of Medical Oncology, Afyon Kocatepe UniversityAfyon, Turkey
| | - Deniz Arslan
- Department of Medical Oncology, Erzurum Training and Research HospitalErzurum, Turkey
| | - Sema Sezgin Göksu
- Department of Medical Oncology, Kayseri Training and Research HospitalKayseri, Turkey
| | | | - Selda Çakal
- Department of Medical Oncology, Akdeniz UniversityAntalya, Turkey
| | - Hakan Şat Bozcuk
- Department of Medical Oncology, Akdeniz UniversityAntalya, Turkey
| | - Burhan Savaş
- Department of Medical Oncology, Akdeniz UniversityAntalya, Turkey
| |
Collapse
|
36
|
Mutlu H, Gündüz S, Büyükçelik A, Yıldız O, Uysal M, Tural D, Bozcuk H, Coşkun HŞ. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b. Clin Genitourin Cancer 2014; 12:447-50. [PMID: 25022784 DOI: 10.1016/j.clgc.2014.06.006] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2014] [Revised: 05/03/2014] [Accepted: 06/03/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND Targeted therapy has improved the survival of patients with metastatic RCC. In the present study, we evaluated whether there was an effect of cytoreductive surgery on prognosis of patients with metastatic RCC using antiangiogenic tyrosine kinase inhibitor (TKI) agents. PATIENTS AND METHODS A total of 52 patients with metastatic RCC from Akdeniz University, Afyon Kocatepe University, and Medipol University participated in the study. All the patients had received targeted antiangiogenic therapy after interferon alfa-2b. According to previous CRN, the patients were divided into 2 groups as CRN (+) and CRN (-). RESULTS The CRN (+) group was younger than the CRN (-) group (P < .001) and the hemoglobin levels were significantly higher in the CRN (+) group (P = .023). The median progression-free survival time from the date of starting TKIs were 8.5 and 3.0 months for the CRN (+) and CRN (-) groups, respectively (P = .104). The median overall survival was 15.1 and 5.4 months for the CRN (+) and CRN (-) groups, respectively (P = .034). CONCLUSION We speculate that CRN is still an important part of treatment modalities in patients with metastatic RCC in modern era targeted therapy, which is currently the best systemic therapy. However, the indications of CRN might be limited to good-risk patients with metastatic RCC. Further randomized studies are warranted to clarify the necessity of CRN in patients with metastatic RCC.
Collapse
Affiliation(s)
- Hasan Mutlu
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey.
| | - Seyda Gündüz
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Abdullah Büyükçelik
- Department of Internal Medicine, Acıbadem University School of Medicine, Istanbul, Turkey
| | - Ozcan Yıldız
- Department of Medical Oncology, Medipol University, Istanbul, Turkey
| | - Mükremin Uysal
- Department of Medical Oncology, Kocatepe University School of Medicine, Afyon, Turkey
| | - Deniz Tural
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hakan Bozcuk
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| | - Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey
| |
Collapse
|
37
|
Abstract
Trastuzumab is one of the most important agents that target human epidermal growth factor receptor 2, but its cardiotoxic effect limits to use it. The mechanism of cardiac dysfunction-related trastuzumab is still unclear. In literature, there is no definite information about the cumulative dose of trastuzumab for cardiotoxicity. In presented case, we reported a breast cancer patient who has been receiving long-term trastuzumab. We have not found any cardiac problems for duration of over four years. According to our case and literature review, we may say that trastuzumab is safely used with periodically echocardiographic control in patients with breast cancer.
Collapse
Affiliation(s)
- Hasan Mutlu
- Department of Medical Oncology, Akdeniz University, Antalya, Turkey
| | | |
Collapse
|
38
|
Sezgin Göksu S, Bilal Ş, Coşkun HŞ. Hepatitis B reactivation related to everolimus. World J Hepatol 2013; 5:43-45. [PMID: 23383366 PMCID: PMC3562726 DOI: 10.4254/wjh.v5.i1.43] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Revised: 09/17/2012] [Accepted: 11/19/2012] [Indexed: 02/06/2023] Open
Abstract
Reactivation of hepatitis B virus (HBV) during chemotherapy is a well known complication in patients with chronic hepatitis B and cancer. The clinical manifestations range from subclinical elevation of liver enzymes to severe, potentially fatal fulminant hepatitis. Reactivation can occur in a patient with previous inactive HBV infection; either an inactive carrier or a patient with resolved hepatitis. Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved in renal cell carcinoma, neuroendocrine tumours and breast cancer. mTOR inhibitors are a new generation of drugs for targeted treatment; therefore, little about their side effects is known. Here, we report a patient with renal cell carcinoma who experienced a flare of hepatitis B infection during treatment with everolimus. Clinicians should be aware of HBV reactivation in patients who are undergoing treatment with everolimus, and screening for hepatitis B infection and prophylactic antiviral treatment should be considered.
Collapse
|
39
|
Ürün Y, Utkan G, Yalcin Ş, Coşkun HŞ, Koçer M, Özdemir NY, Kaplan MA, Arslan ÜY, Özdemir F, Öztuna D, Akbulut H, İçli F. Lack of any relationship between ABO and Rh blood groups and clinicopathological features in patients with gastrointestinal stromal tumors: Turkish Oncology Group. Asian Pac J Cancer Prev 2012; 13:4129-4131. [PMID: 23098529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/01/2023] Open
Abstract
BACKGROUND An association between the ABO blood group and the risk of certain malignancies, including pancreatic and gastric cancer, has been reported previously. However, it is unclear whether this association is valid for gastrointestinal stromal tumors (GIST). In this study, ABO blood groups and the Rh factor were investigated in a series of GIST cases. MATERIAL AND METHODS In 162 patients with GIST, blood group and Rh factor were examined and compared with a control group of 3,022,883 healthy volunteer blood donors of the Turkish Red Crescent between 2004 and 2011. The relationship of blood groups with tumor size, mitotic activity, and age were also evaluated. RESULTS Overall, the ABO blood group and Rh factor distributions of the 162 patients with GIST were similar to those of the general population. There were no significant differences between both ABO blood types and Rh factor in terms of tumor size, mitotic activity, and age. CONCLUSION This is the first study reported on this issue. In our study, we didn't find any relationship between GIST and ABO blood group and Rh factor. However further studies with larger number of patients are needed to establish the role of blood groups in this population.
Collapse
Affiliation(s)
- Yüksel Ürün
- Faculty of Medicine, Ankara University, Turkey
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Coşkun HŞ, Coşkun D, Durak S, Aydin S, Yildiz M. Specialist physicians should be aware of the national cancer control and screening program: a report from medical oncologists in Turkey. Asian Pac J Cancer Prev 2011; 12:337. [PMID: 21517283] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023] Open
|
41
|
Coşkun HŞ, Kargı A, Özdoğan M, Bozcuk H, Savaş B. Leukocytosis, thrombocytosis and hypercalcemia as a triple paraneoplastic syndrome in a patient with squamous cell carcinoma of the renal pelvis. Turk J Haematol 2010; 27:51-52. [PMID: 27265802] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
Affiliation(s)
- Hasan Şenol Coşkun
- Department of Medical Oncology, Akdeniz University School of Medicine, Antalya, Turkey Phone: +90 242 249 67 37 E-mail:
| | | | | | | | | |
Collapse
|
42
|
Coşkun HŞ, İlhan O, Özcan M, Ayaz S, Dalva K, Üstün C, Arat M. Serum transforming growth factor beta 1 levels in multiple myeloma patients. Turk J Haematol 2006; 23:47-52. [PMID: 27265228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
Abstract
Cytokinesis plays an important role in the etiology of multiple myeloma. The transforming growth factor (TGF) beta 1 levels in 82 sera from 60 patients with multiple myeloma were analyzed by ELISA. Fourty one sample were obtained before treatment from newly diagnosed patients, 22 after treatment from the same patients and 19 from relapsed/refractory patients. Serum median TGF level of newly diagnosed patients was 769.5 ng/mL (126-1853), and the relapsed/refractory patients had similar levels. TGF levels after chemotherapy were not different between patients that reached plateau phase and those who remained refractory. We found a negative correlation between TGF and C-reactive protein and blood urea nitrogen and a positive correlation between TGF and hemoglobin level in newly diagnosed patients. After treatment, it was determined that TGF levels at diagnosis were higher in patients who reached plateau phase than in the refractory patients. Elevated serum TGF concentration at diagnosis in multiple myeloma patients may be a favorable predictor of response.
Collapse
|
43
|
Arslan Ç, Coşkun HŞ. Thrombocytosis in solid tumors: review of the literature. Turk J Haematol 2005; 22:59-64. [PMID: 27264662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
|
44
|
Coşkun HŞ, Er Ö, Tanrıverdi F, Altınbaş M. Hypereosinophilia as a Preclinical Sign of Tongue Squamous Cell Cancer in a Gastric Cancer Patient with Complete Remission. Turk J Haematol 2003; 20:107-110. [PMID: 27265441] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
Abstract
Although parasitic infestations and allergic disorders are the most common causes of eosinophilia it may also occompany malignant diseases. Many studies suggested that eosinophilia is related to tumor dissemination or necrosis. We are presenting a case; 10 months after gastric carcinoma operation who had severe eosinophilia with bone marrow and skin infiltration that gave response to steroid therapy. After three months, tongue squamous cell carsinoma as a second malignancy occurred in our patient that the eosinophilia could be the preclinical sign of the second cancer.
Collapse
|
45
|
Coşkun HŞ, Eser B, Çetin M, Er Ö, Ünal A, Altınbaş M, Karahacıoğlu E, Kaplan B. Hodgkin's Disease: Results of a Single Center in Central Anatolia. Turk J Haematol 2001; 18:117-122. [PMID: 27264066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
Abstract
Hodgkin's Disease (HD) accounts for about 1% of newly diagnosed malignant diseases. In this study 119 HD cases followed in Erciyes University Hospital were evaluated. 67.2% of the patients was male, 32.8% female. The patients' age ranged from 15 to 72 years with a median of 41.5 years. Of the patients 10.1% was stage I, 29.4% stage II, 39.5% stage III, and 21.0% stage IV. According to Rye classification frequency of histologic subtypes was as follows; 21.0% lymphocyte predominant, 25.2% nodular sclerosis, 43.7% mixed cellularity, and 10.1% lymphocyte depletion. Combination chemotherapy consisting cyclophosphamide, vincristine, procarbazine and prednisolone (COPP) was used as first line treatment in 59.7% of patients. Complete remission was achieved in 84.9% of patients and partial remission in 5.0% of patients; response could not be obtained in remaining 10.1% of patients. Disease progression or recurrence was observed in 30.2% of patients. Five year survival rate was found as 70.8% of all patients, 90.1% for stage I-II, 55.3% for stage III-IV patients (p= 0.03).
Collapse
|
46
|
Çelebi H, Üstün C, Arat M, Akan H, Tunçman G, Özçelik T, Coşkun HŞ, Koç H. An Extra Benefit of Allogeneic Peripheral Blood Stem Cell Transplantation in a Patient with Lymphoblastic Lymphoma: Cure of Thalassemia Minor. Turk J Haematol 2000; 16:77-79. [PMID: 27265858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/05/2023] Open
Abstract
b thalassemia minor is frequent in mediterranean countries. It is a benign disorder and does not warrant any therapeutical intervention. We transplanted a 25-year-old Turkish male who was diagnosed as lymphoblastic lymphoma and had b thalassemia minor as well. He received peripheral blood stem cells transplantation from his HLA-identical sibling who was not a carrier of b thalassemia. After the allogeneic transplantation we did not only observe remission of the lymphoblastic lymphoma but also the disappearance of b thalassemia minor.
Collapse
|